Mikako Ishijima

473 total citations
15 papers, 176 citations indexed

About

Mikako Ishijima is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Mikako Ishijima has authored 15 papers receiving a total of 176 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 4 papers in Surgery. Recurrent topics in Mikako Ishijima's work include Cancer Immunotherapy and Biomarkers (6 papers), Lung Cancer Treatments and Mutations (5 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (4 papers). Mikako Ishijima is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Lung Cancer Treatments and Mutations (5 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (4 papers). Mikako Ishijima collaborates with scholars based in Japan. Mikako Ishijima's co-authors include Takeshi Uenami, Yuki Akazawa, Masaki Kanazu, Yukihiro Yano, Masahide Mori, Toshihiko Yamaguchi, Yuki Hosono, Soichiro Yokota, Kohei Nishida and Ryuya Edahiro and has published in prestigious journals such as PLoS ONE, Lung Cancer and British Journal of Radiology.

In The Last Decade

Mikako Ishijima

14 papers receiving 174 citations

Peers

Countries citing papers authored by Mikako Ishijima

Since Specialization

Citations

This map shows the geographic impact of Mikako Ishijima's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mikako Ishijima with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mikako Ishijima more than expected).

Fields of papers citing papers by Mikako Ishijima

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mikako Ishijima. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mikako Ishijima. The network helps show where Mikako Ishijima may publish in the future.

Co-authorship network of co-authors of Mikako Ishijima

This figure shows the co-authorship network connecting the top 25 collaborators of Mikako Ishijima. A scholar is included among the top collaborators of Mikako Ishijima based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mikako Ishijima. Mikako Ishijima is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	EGFR‐mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib 2021 ·Thoracic Cancer ·Reina Hara, Masaki Kanazu, (unknown), Tomoki Kuge, Mikako Ishijima, Takeshi Uenami, Yuki Akazawa, Yukihiro Yano, Toshihiko Yamaguchi, Masahide Mori	1
2	Expectoration of tonsillar metastasis of pulmonary pleomorphic carcinoma after pseudoprogression: A case report 2021 ·Thoracic Cancer ·Tomoki Kuge, (unknown), Yuji Yamamoto, Mikako Ishijima, Takeshi Uenami, Masaki Kanazu, Yuki Akazawa, Yukihiro Yano, Toshihiko Yamaguchi, Masahide Mori	3
3	Safety and effectiveness of pirfenidone combined with carboplatin‐based chemotherapy in patients with idiopathic pulmonary fibrosis and non‐small cell lung cancer: A retrospective cohort study 2020 ·Thoracic Cancer ·Yuji Yamamoto, Yukihiro Yano, Tomoki Kuge, (unknown), Mikako Ishijima, Takeshi Uenami, Masaki Kanazu, Yuki Akazawa, Toshihiko Yamaguchi, Masahide Mori	20
4	Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune‐related adverse effect: A case report 2019 ·Thoracic Cancer ·Ryuya Edahiro, Mikako Ishijima, (unknown), Kohei Nishida, Takeshi Uenami, Masaki Kanazu, Yuki Akazawa, Yukihiro Yano, Masahide Mori	12
5	A case of meningoencephalitis associated with pembrolizumab treated for squamous cell lung cancer 2019 ·Rinsho Shinkeigaku ·(unknown), Mikako Ishijima, Keiko Toyooka, Harutoshi Fujimura	7
6	Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study 2018 ·PLoS ONE ·Yukihiro Yano, (unknown), Ryuya Edahiro, Yuki Hosono, (unknown), Kohei Nishida, (unknown), Mikako Ishijima, Takeshi Uenami, Masaki Kanazu, Yuki Akazawa, Toshihiko Yamaguchi, Masahide Mori	6
7	Two cases of response to pembrolizumab in epidermal growth factor receptor mutated lung adenocarcinoma patients with programmed death-ligand 1 overexpression 2018 ·Annals of Translational Medicine ·Takeshi Uenami, Mikako Ishijima, Masaki Kanazu, (unknown), Ryuya Edahiro, Kohei Nishida, Yuki Akazawa, Yukihiro Yano, Toshihiko Yamaguchi, Masahide Mori	3
8	Hyperprogressive disease in patients with non‐small cell lung cancer treated with nivolumab: A case series 2018 ·Thoracic Cancer ·Masaki Kanazu, Ryuya Edahiro, (unknown), Kohei Nishida, Mikako Ishijima, Takeshi Uenami, Yuki Akazawa, Yukihiro Yano, Toshihiko Yamaguchi, Masahide Mori	22
9	Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report 2017 ·Lung Cancer ·Takeshi Uenami, Yuki Hosono, Mikako Ishijima, Masaki Kanazu, Yuki Akazawa, Yukihiro Yano, Masahide Mori, Toshihiko Yamaguchi, Soichiro Yokota	36
10	Case series of pleomorphic carcinomas of the lung treated with nivolumab 2017 ·Thoracic Cancer ·Masaki Kanazu, Takeshi Uenami, Yukihiro Yano, (unknown), Yuki Hosono, Mikako Ishijima, Yuki Akazawa, Toshihiko Yamaguchi, (unknown), Masahide Mori, Soichiro Yokota	38
11	Radiation Pneumonitis with Eosinophilic Alveolitis in a Lung Cancer Patient 2017 ·Internal Medicine ·Yuki Hosono, (unknown), (unknown), Mikako Ishijima, Takeshi Uenami, Masaki Kanazu, Yuki Akazawa, Yukihiro Yano, Masahide Mori, Toshihiko Yamaguchi, Soichiro Yokota	1
12	Successful treatment with gefitinib after Stevens–Johnson syndrome associated with afatinib therapy in a patient with adenocarcinoma of the lung 2016 ·International Cancer Conference Journal ·Tomoyuki Otsuka, Aya Tanaka, Hiroaki Azukizawa, Shoko Sasaki, Mikako Ishijima, Takanori Matsuki, Akio Osa, Takeshi Nakatani, Muneyoshi Kuroyama, Haruhiko Hirata, Takashi Kijima	6
13	A Case of Lung Adenocarcinoma with Drug-induced Lung Disease due to Nivolumab in the Early Period After Its First Administration 2016 ·Haigan ·Yuki Hosono, Yukihiro Yano, Mikako Ishijima, Takeshi Uenami, Yuki Akazawa, Masahide Mori	0
14	Patients with severe emphysema have a low risk of radiation pneumonitis following stereotactic body radiotherapy 2014 ·British Journal of Radiology ·Mikako Ishijima, Hidetsugu Nakayama, (unknown), (unknown), (unknown), (unknown), (unknown), Koichi Tokuuye	20
15	[A case of hepatocellular carcinoma presumably transforming to malignant spindle cell tumor]. 1995 ·PubMed ·Mikako Ishijima, Mitsugu Tanaka, (unknown), (unknown), (unknown), Kikukatsu Ito, Kazufumi Tsubaki, (unknown), Yoshiki Arakawa, Nanao Negishi	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact